Sanofi Pasteur Starts Phase II Trial for Influenza Vaccine
Posted on: Thursday, 8 November 2007, 12:00 CST
Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, has initiated Phase II testing of its cell culture-based seasonal influenza vaccine in the US.
This project is part of a contract awarded in 2005 by the US Department of Health and Human Services (HHS) for the development of a new cell culture- based influenza vaccine. Phase II trials involving healthy adult volunteers in the US will focus further on the safety profile and immunogenicity of the cell-based vaccine.
This vaccine was developed using the PER.C6 cell line, licensed from Dutch biotechnology company Crucell. PER.C6 Cell technology offers Sanofi Pasteur a promising and reliable production method for seasonal and pandemic influenza vaccines in addition to traditional, proven egg-based production, the company said.
Source: Datamonitor
Related Articles
- ImmunoCellular to File IND Application for Cancer Stem Cell Vaccine
- ImmunoCellular Therapeutics Announces Completion of Proof-of-Principle Studies Demonstrating Efficacy of Cancer Stem Cell Vaccine in Preclinical Model
- Opexa Testing T-Cell Vaccine for MS
- HepaLife's Patented 'PBS-1' Cells for Avian Influenza Vaccine Achieve FDA's Early Guidance Research Objective
- MedImmune Files Investigational New Drug Application for Cell Culture-Based Influenza Vaccine
- CytoDyn Announces Progress With DNA Pre-Vaccines for Influenza
- IDM Presents Results of Its Phase I Trial of Its Collidem(R) Dendritic Cell Vaccine in Patients With Advanced Colorectal Cancer at GI-ASCO Meeting in San Francisco
- Argos Therapeutics and DC Bio Corp. Announce New Clinical Trial to Begin for Chronic Lymphocytic Leukemia Using Argos' Personalized Dendritic Cell Vaccine
- Crucell Updates Progress in Scale-Up of Cell-Culture-Based Influenza Vaccine Programs
- Tregs in T Cell Vaccination: Exploring the Regulation of Regulation
 |
 |
User Comments (0)
RSS Feeds